Hemophilia A

What is Hemophilia A?

Hemophilia A is the most common type of hemophilia and is caused by deficient or dysfunctional clotting factor VIII. Although hemophilia A is usually inherited, about 30% of cases are caused by a spontaneous mutation in the person’s own genes. 

Hemophilia A affects about 1 in 12,000 people and is diagnosed by taking a blood sample and measuring the level of factor activity in the blood. Hemophilia A is diagnosed by testing the level of factor VIII activity in the blood. 

Hemophilia A can be mild, moderate, or severe, depending on how much clotting factor is in an affected person's blood. However, about 60% of patients have the severe form of the disorder. People with hemophilia A have prolonged bleeding after an injury, surgery, or tooth extraction. In severe cases, they may bleed once or twice a week and often the bleeding is spontaneous, which means it happens for no obvious reason. Serious complications can result from bleeding into the joints, muscles, brain, or other internal organs. In a mild case of hemophilia A, the disorder may remain unknown until after a surgery or serious injury.

Treatment for hemophilia A is very effective and with appropriate treatment and care, people with hemophilia A can live perfectly healthy lives. The main treatment is called replacement therapy, during which clotting factor VIII is infused into a vein either prophylactically (preventatively) or on-demand to prevent or treat bleeds.

Resources for you

RESOURCE DESCRIPTION
All About Bleeding Information and resources to help treat and manage life with a bleeding disorder. View Website
  All About Bleeding Discussion guides View Website
Signs of Bleeding The 5 signs of a bleeding disorder View Website
World Federation of Hemophilia A global organization aiming to improve and sustain care for people with inherited bleeding disorders.
View Website
National Hemophilia Foundation A U.S. organization dedicated to finding better treatments and cures for inheritable bleeding disorders.
View Website
Hemophilia Federation of America A U.S. a national nonprofit organization that assists and advocates for the bleeding disorders community.
View Website
Product Websites AFSTYLA.com (United States)
Humate-P.com (United States)
HelixateFS.com (United States)
Beriate.de (Germany)
 

Treatments Available

Availability of treatments may vary from country to country. Please be sure to visit your local CSLBehring.com site for further information.

AFSTYLA® Antihemophilic Factor (Recombinant), Single Chain Visit Website pdf
Humate-P® / Haemate® P Antihemophilic Factor/von Willebrand Factor Complex (Human) Visit Website pdf
Biostate®      
Voncento®
     
Stimate®
(Desmopressin acetate) Nasal Spray, 1.5 mg/mL   pdf
Octostim®      
Helixate®FS / Helixate® NexGen
 Antihemophilic Factor (Recombinant) Formulated with Sucrose Visit Website pdf
Monoclate-P®
Antihemophilic Factor (Human) Factor VIII:C Pasteurized Monoclonal Antibody Purified   pdf
Beriate®   Visit Website  

Current Clinical Trials

Please see below for any current clinical trials for this condition.

Condition Description
 Hemophilia A An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A. Learn More
Looking down into microscope and taking notes

Participate in Clinical Trials

Discover what is involved in participating in one of our clinical trials and how you can enroll.

Learn More

Get our latest news in your inbox

mail@example.com
First name
Last name
Country

Thanks!

You have now been added
to the CSL Behring news list